NCT06454188

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis (UP-SPOUT)

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: CARE ARTHRITIS LTD. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)

Conditions

• Psoriatic Arthritis
• Spondyloarthritis, Axial

Interventions

Type	Name	Description
DRUG	Upadacitinib 15 MG [Rinvoq]	15mg tablet once per day.
DRUG	Placebo	15mg tablet once per day.

Timeline

• Start date: 2024-12-03
• Primary completion: 2028-09-01
• Completion: 2028-10-01
• First posted: 2024-06-12
• Last updated: 2026-04-03

Locations

5 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study